Labiotech.eu

More News! 10 Nov 2022

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Avstera receives funding for cancer programs

Avstera Therapeutics Corp. has announced the completion of its seed round to advance its lead cancer programs geared toward targeting solid tumors. The company intends to use the $4.55 million proceeds to enable its lead highly specific HDAC6i for IND filing targeting locally advanced and metastatic solid tumors by the end of next year. “Tumor […]

November 10, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Researchers develop new nanoparticle to deliver drugs direct to macrophages

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

More News! 10 Nov 2022

Novo Nordisk supports Plant2Food platform with €27M funding

Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […]

November 10, 2022 - 4 minutesmins - By Liza Laws

News and Trends 10 Nov 2022

Ascentage Pharma gets Chinese approval for solid tumor study

Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the study in the […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Novel branched lipid boosts mRNA delivery to cells

A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

The red cancer cell uses the white protein Memo1 to bind the green copper ions.

News and Trends 10 Nov 2022

Looking for cancer clues? Copper may open new drug treatment doors

For cancer cells to grow and spread around the human body, they need proteins that bind copper ions. New research about how cancer-related proteins bind the metal and how they interact with other proteins may open up potential new drug targets in the fight against cancer. Human cells need small amounts of the metal copper […]

November 10, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

New radiopharmaceutical shrinks prostate cancer tumors

Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

NRG Therapeutics, Ltd. has closed a £16 million ($18.2 million) series A financing. The funding was led by Omega Funds and joined by additional new investor Brandon Capital and founding investor Parkinson’s Virtual Biotech. NRG Therapeutics is using mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as […]

November 10, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 10 Nov 2022

The five hottest biotech startup companies in Brazil

Brazil’s developing economy is supporting an emerging biotech startup scene. Catch a glimpse of the biotech companies causing a stir in Brazil. Over the decades, Brazil has grown into an agricultural powerhouse and has the biggest economy in South America. The nation is the world’s second-largest producer of biotech crops, with increasing land devoted to […]

November 10, 2022 - 4 minutesmins - By Jonathan Smith

More News! 9 Nov 2022

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […]

November 9, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing

Avstera receives funding for cancer programs

Researchers develop new nanoparticle to deliver drugs direct to macrophages

Novo Nordisk supports Plant2Food platform with €27M funding

Ascentage Pharma gets Chinese approval for solid tumor study

Novel branched lipid boosts mRNA delivery to cells

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Looking for cancer clues? Copper may open new drug treatment doors

New radiopharmaceutical shrinks prostate cancer tumors

Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS

The five hottest biotech startup companies in Brazil

PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!